Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review

2021 ◽  
Author(s):  
Laeth L George ◽  
Saarang R Deshpande ◽  
Matthew J Cortese ◽  
Ellen K Kendall ◽  
Asmi Chattaraj ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Cellular Therapy ◽  
Refractory Multiple Myeloma

scholarly journals Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis

2017 ◽  
Vol 8 (10) ◽  
pp. 1801-1808 ◽  
Author(s):  
Runzhe Chen ◽  
Yujie Wang ◽  
Chengxin Luan ◽  
Chong Gao ◽  
Xiaoping Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Meta Analysis ◽  
Refractory Multiple Myeloma

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

2018 ◽  
Vol 26 (7) ◽  
pp. 2075-2090 ◽  
Author(s):  
Francesco Sparano ◽  
Michele Cavo ◽  
Pasquale Niscola ◽  
Tommaso Caravita ◽  
Fabio Efficace
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Patient Reported Outcomes ◽  
Refractory Multiple Myeloma ◽  
Patient Reported

Quality of life of treatment for relapsed/refractory multiple myeloma: a systematic review

2019 ◽  
Vol 19 (10) ◽  
pp. e278
Author(s):  
Maria Nassim ◽  
Jonas Nilsson ◽  
Stojan Zavisic ◽  
Mia Malmenäs ◽  
Iain Fotheringham ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Multiple Myeloma ◽  
Refractory Multiple Myeloma

Efficacy of Single-Agent Bortezomib Versus Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma: A Systematic Review.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5160-5160
Author(s):  
Miles Prince ◽  
Michael Adena ◽  
Dell Kingsford Smith ◽  
Judy Hertel
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Response Rate ◽  
English Literature ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Free Survival ◽  
Refractory Multiple Myeloma ◽  
One Year ◽  
Intent To Treat

Abstract Aim: To perform a systematic review of the efficacy of monotherapy with bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma. Methods: Published English literature from 1966 to June 2005 (MEDLINE, EMBASE, Cochrane library), publication reference lists, Janssen-Cilag Pty Ltd data-on-file, and abstracts from recent multiple myeloma conferences were reviewed. Prospective studies containing at least a single arm of any treatment group with n ≥ 30 and using continuing or variable thalidomide dosing were included. Studies adding dexamethasone for non-responders were excluded. Outcomes were analysed on an intent-to-treat basis. Statistical pooling was performed where possible for the following outcome measures: primary outcome of response rate, defined by a serum M-protein reduction ≥50% (A) and strict (e.g. EBMT) criteria (B), and for the secondary outcomes of overall survival and progression-free survival. Results: One bortezomib (n=333, APEX, NEJM2005, 352; 2487–98) and 15 thalidomide (n=1007) studies were included. Patient baseline characteristics including age, gender, IgG:IgA, disease duration and β2M were well matched, except that 48% of bortezomib patients had received prior thalidomide. On an intent-to-treat basis, the overall estimate for response rate (A) was 53% for patients receiving bortezomib versus 32% for thalidomide (p<0.001, n=10 studies). For response rate (B) the estimate was 36% for patients receiving bortezomib versus 22% for thalidomide (p<0.001, n=4 studies). One-year survival was 81% for patients receiving bortezomib versus 67% for thalidomide (p<0.001, n=6 studies). Due to differences in disease monitoring and definitions of progression, it was not possible to compare results for progression-free survival. Conclusion: In patients with relapsed or refractory multiple myeloma, bortezomib achieved significantly higher response rates and longer one-year survival than thalidomide, despite 48% of bortezomib-treated patients having received prior thalidomide.

scholarly journals A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

2008 ◽  
Vol 81 (4) ◽  
pp. 247-252 ◽  
Author(s):  
Marie von Lilienfeld-Toal ◽  
Corinna Hahn-Ast ◽  
Kerstin Furkert ◽  
Florian Hoffmann ◽  
Ralph Naumann ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Combination Therapy ◽  
Phase Ii ◽  
Phase Ii Trials ◽  
Refractory Multiple Myeloma

scholarly journals Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma

Oncotarget ◽  
2017 ◽  
Vol 8 (20) ◽  
pp. 34001-34017 ◽  
Author(s):  
Tiantian Zhang ◽  
Sen Wang ◽  
Tengfei Lin ◽  
Jingmei Xie ◽  
Lina Zhao ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document